Free Trial

Neurogene (NGNE) SEC Filings & 10K Form

$32.11
+0.62 (+1.97%)
(As of 05/24/2024 ET)

Recent Neurogene SEC Filings

DateFilerForm TypeView
05/10/2024
6:31 AM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2024
5:20 AM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/26/2024
1:33 PM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form DEF 14A
04/26/2024
1:33 PM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form ARS
04/26/2024
1:34 PM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form DEFA14A
04/22/2024
3:44 PM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/02/2024
2:43 PM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/14/2024
7:51 PM
Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/14/2024
7:53 PM
Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/14/2024
7:54 PM
McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
3:29 PM
Babler Martin (Reporting)
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
5:20 PM
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
Smith Sean Michael (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
6:30 AM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/20/2024
3:16 PM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/14/2024
5:05 PM
EcoR1 Capital, LLC (Filed by)
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
Form SC 13G
02/14/2024
8:19 AM
Lynx1 Capital Management LP (Filed by)
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
Form SC 13G/A
02/09/2024
3:35 PM
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
SIMPSON TODD E (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/18/2024
5:56 PM
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Noonberg Sarah B. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/18/2024
5:58 PM
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
PALEKAR ROHAN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/18/2024
6:01 PM
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Woods Robert Keith (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/18/2024
5:45 PM
Jordan Julie (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
01/18/2024
5:48 PM
Jordan Julie (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/18/2024
5:51 PM
BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/18/2024
5:53 PM
Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
6:11 AM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/26/2023
5:04 PM
Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
12/26/2023
5:05 PM
Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
12/26/2023
5:10 PM
BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
12/26/2023
5:10 PM
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Woods Robert Keith (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
12/26/2023
5:12 PM
McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
12/26/2023
5:16 PM
Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
12/20/2023
5:43 PM
667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2023
4:24 PM
BAKER BROS. ADVISORS LP (Filed by)
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
Form SC 13D/A
12/19/2023
6:31 AM
Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/06/2023
3:21 PM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/06/2023
3:24 PM
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Form 425
12/04/2023
4:10 PM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/04/2023
4:14 PM
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Form 425
11/13/2023
11:15 PM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form EFFECT
11/08/2023
1:34 PM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form S-4/A
10/18/2023
3:09 PM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form S-4/A
Tech GIANT’s Plans to Revolutionize Crypto… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.
10/10/2023
3:42 PM
BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Form SC 13D/A
10/10/2023
3:22 PM
667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neoleukin Therapeutics, Inc. (Issuer)
Neoleukin Therapeutics, Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/05/2023
11:50 AM
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Form 425
09/28/2023
3:28 PM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form S-4/A
09/22/2023
7:03 AM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/17/2023
4:08 PM
667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neoleukin Therapeutics, Inc. (Issuer)
Neoleukin Therapeutics, Inc. (Issuer)
Neurogene (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/17/2023
4:12 PM
BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Form SC 13D/A
07/27/2023
4:15 PM
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Redmile Group, LLC (Filed by)
Form SC 13D
07/19/2023
4:28 PM
BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Form SC 13D/A
07/18/2023
7:34 AM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/18/2023
7:37 AM
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Form 425
06/12/2023
11:57 AM
Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:NGNE) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners